Vivek Ramaswamy is everywhere. You've seen him on the debate stage, heard him on every podcast under the sun, and now he’s leading the Department of Government Efficiency (DOGE) alongside Elon Musk. But long before he was trying to "slash and burn" the federal bureaucracy, he was a prolific, almost manic, company builder.
Honestly, the list of Vivek Ramaswamy organizations founded is kind of exhausting to track. It’s not just one or two companies; it’s a whole ecosystem of "Vants," index funds, and even a social media network for college kids that most people have totally forgotten about.
If you want to understand the man, you have to look at the paper trail of his LLCs and C-corps. He doesn't just start businesses; he builds "platforms" designed to disrupt industries he thinks have gone soft or "woke."
The Roivant Era: Building the "Alphabet of Healthcare"
In 2014, a 29-year-old Ramaswamy founded Roivant Sciences. The "ROI" in the name literally stands for "Return on Investment." Subtle? No. Effective? For a while, absolutely.
The business model was basically dumpster diving for drugs. He’d go to giant pharmaceutical companies like GlaxoSmithKline and buy the rights to "abandoned" drug candidates—medicines that had failed or were shelved for non-scientific reasons—and then spin them off into their own dedicated companies. These were the "Vants."
👉 See also: How Much Do Chick fil A Operators Make: What Most People Get Wrong
The Famous (and Infamous) Vants
- Axovant Sciences: This is the one everyone brings up at parties (if you go to very nerdy parties). In 2015, Axovant had the biggest biotech IPO in US history at the time. They were chasing a "miracle" drug for Alzheimer’s called intepirdine. It failed spectacularly in Phase 3 trials in 2017. The stock tanked. Vivek later said he had no regrets because "scientific failure is part of the process."
- Myovant Sciences: A much bigger win. This one focused on women’s health and prostate cancer. It eventually got FDA approvals and was part of a massive $3 billion deal with Sumitomo Dainippon Pharma in 2019.
- Dermavant: Focused on skin stuff, like psoriasis.
- Enzyvant: Targeted rare diseases.
- Datavant: This wasn't a drug company; it was a data-sharing platform for healthcare. It merged with Ciox in 2021 in a deal valued at around $7 billion.
Ramaswamy’s brilliance—or his "con," depending on who you ask—was the decentralized model. By 2019, Roivant had over 40 drugs in development across 14 different areas. He stepped down as CEO in 2021, but the "Vant" machine is still humming along without him.
Strive Asset Management: The "Anti-Woke" Pivot
After leaving Roivant, Vivek didn't just retire to a beach. He wrote Woke, Inc. and decided the next thing that needed fixing was Wall Street.
In 2022, he co-founded Strive Asset Management in Columbus, Ohio. The goal was simple: provide an alternative to the "Big Three" (BlackRock, State Street, and Vanguard). He argued these giants were using your retirement money to push political agendas like ESG (Environmental, Social, and Governance) and DEI (Diversity, Equity, and Inclusion).
Strive’s pitch? "Excellence Capitalism."
✨ Don't miss: ROST Stock Price History: What Most People Get Wrong
Basically, they told companies like Chevron and Disney to stop worrying about social justice and just focus on making a profit. Their flagship fund, DRLL, was an energy sector ETF that didn't care about carbon footprints.
The 2025 Bitcoin Evolution
As of late 2025, Strive has taken a wild turn. Under new CEO Matt Cole, the firm merged with Asset Entities and is now essentially a "Bitcoin Treasury" company. They’ve started buying up massive amounts of Bitcoin—holding over 10,000 BTC—and even launched a Bitcoin Bond ETF. It’s a far cry from just fighting ESG; it’s now a bet on the future of decentralized finance.
The Ones You Didn’t Know About
Most people think Vivek’s career started with Roivant. Not true.
Back in 2007, fresh out of Harvard, he co-founded Campus Venture Network. It was a private social networking site for student entrepreneurs. Think LinkedIn, but specifically for kids trying to build the next Facebook. He sold it to the Ewing Marion Kauffman Foundation in 2009.
🔗 Read more: 53 Scott Ave Brooklyn NY: What It Actually Costs to Build a Creative Empire in East Williamsburg
Then there’s Chapter.
Founded in 2020, Chapter is a Medicare navigation platform. It’s designed to help seniors figure out which health plans actually cover their doctors and meds. It’s a surprisingly "normal" business for someone who spends his time fighting the deep state. While Ramaswamy stepped away from the board to run for President, the company recently raised $75 million to expand.
Why Do These Organizations Matter?
When you look at Vivek Ramaswamy organizations founded, a pattern emerges. He likes "toll booth" businesses—platforms that sit in the middle of a complex system and extract value by making it more efficient (or "depoliticized").
- Roivant made drug development "efficient" by recycling assets.
- Strive tried to make investing "efficient" by removing political friction.
- Chapter makes Medicare "efficient" by simplifying the choice architecture.
- DOGE (his current project) is the ultimate version of this—trying to make the entire U.S. government "efficient" by, well, deleting the parts he thinks don't work.
What’s Next for the "Vivek Ecosystem"?
If you're tracking these companies for investment or just curiosity, keep an eye on Strive’s transition into a Bitcoin powerhouse. It’s a high-risk move that mirrors Vivek’s own high-stakes political career.
Also, watch Roivant (NASDAQ: ROIV). It has outlived its founder’s tenure and remains a legitimate heavyweight in the biotech space, proving that even if Axovant was a bust, the underlying model had legs.
Actionable Insights:
- For Investors: Understand that Strive is no longer just an "anti-woke" fund; it is now a crypto-adjacent play. Check their Bitcoin holdings before jumping in.
- For Healthcare Proponents: Roivant’s "Vant" model is being copied by other firms like BridgeBio. It’s a valid way to look for "under-priced" medical innovation.
- For Political Observers: The "efficiency" playbook Vivek used at Roivant is the exact blueprint he’s using for the Department of Government Efficiency in 2026. If he treats the Dept. of Education like he treated a failing drug trial, expect it to be "terminated" quickly.
The story of Vivek’s organizations is a story of rapid scaling, occasionally loud failures, and a relentless focus on what he calls "meritocracy." Whether he's a visionary or just a master of the pivot, he’s certainly not boring.
Next Steps for You: If you want to dig deeper into the actual performance of these companies, you can look up the SEC filings for Roivant Sciences (ROIV) and Strive Inc. (ASST) to see the raw numbers behind the rhetoric. Keep a close eye on the July 4, 2026 deadline for DOGE—it's the next major "exit" for his current organizational experiment.